Treatment-resistant depression (TRD) is a major contributor to the disability caused by major depressive disorder (MDD). Primary care electronic health records provide an easily accessible approach to investigate TRD clinical and genetic characteristics. MDD defined from primary care records in UK Biobank (UKB) and EXCEED studies was compared with other measures of depression and tested for association with MDD polygenic risk score (PRS). Using prescribing records, TRD was defined from at least two switches between antidepressant drugs, each prescribed for at least 6 weeks. Clinical-demographic characteristics, SNP-based heritability (h2SNP) and genetic overlap with psychiatric and non-psychiatric traits were compared in TRD and non-TRD MDD cases. In 230,096 and 8926 UKB and EXCEED participants with primary care data, respectively, the prevalence of MDD was 8.7% and 14.2%, of which 13.2% and 13.5% was TRD, respectively. In both cohorts, MDD defined from primary care records was strongly associated with MDD PRS, and in UKB it showed overlap of 71–88% with other MDD definitions. In UKB, TRD vs healthy controls and non-TRD vs healthy controls h2SNP was comparable (0.25 [SE = 0.04] and 0.19 [SE = 0.02], respectively). TRD vs non-TRD was positively associated with the PRS of attention deficit hyperactivity disorder, with lower socio-economic status, obesity, higher neuroticism and other unfavourable clinical characteristics. This study demonstrated that MDD and TRD can be reliably defined using primary care records and provides the first large scale population assessment of the genetic, clinical and demographic characteristics of TRD.

Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts / Fabbri C.; Hagenaars S.P.; John C.; Williams A.T.; Shrine N.; Moles L.; Hanscombe K.B.; Serretti A.; Shepherd D.J.; Free R.C.; Wain L.V.; Tobin M.D.; Lewis C.M.. - In: MOLECULAR PSYCHIATRY. - ISSN 1359-4184. - STAMPA. - 26:7(2021), pp. 3363-3373. [10.1038/s41380-021-01062-9]

Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts

Fabbri C.
Primo
;
Serretti A.;
2021

Abstract

Treatment-resistant depression (TRD) is a major contributor to the disability caused by major depressive disorder (MDD). Primary care electronic health records provide an easily accessible approach to investigate TRD clinical and genetic characteristics. MDD defined from primary care records in UK Biobank (UKB) and EXCEED studies was compared with other measures of depression and tested for association with MDD polygenic risk score (PRS). Using prescribing records, TRD was defined from at least two switches between antidepressant drugs, each prescribed for at least 6 weeks. Clinical-demographic characteristics, SNP-based heritability (h2SNP) and genetic overlap with psychiatric and non-psychiatric traits were compared in TRD and non-TRD MDD cases. In 230,096 and 8926 UKB and EXCEED participants with primary care data, respectively, the prevalence of MDD was 8.7% and 14.2%, of which 13.2% and 13.5% was TRD, respectively. In both cohorts, MDD defined from primary care records was strongly associated with MDD PRS, and in UKB it showed overlap of 71–88% with other MDD definitions. In UKB, TRD vs healthy controls and non-TRD vs healthy controls h2SNP was comparable (0.25 [SE = 0.04] and 0.19 [SE = 0.02], respectively). TRD vs non-TRD was positively associated with the PRS of attention deficit hyperactivity disorder, with lower socio-economic status, obesity, higher neuroticism and other unfavourable clinical characteristics. This study demonstrated that MDD and TRD can be reliably defined using primary care records and provides the first large scale population assessment of the genetic, clinical and demographic characteristics of TRD.
2021
Genetic and clinical characteristics of treatment-resistant depression using primary care records in two UK cohorts / Fabbri C.; Hagenaars S.P.; John C.; Williams A.T.; Shrine N.; Moles L.; Hanscombe K.B.; Serretti A.; Shepherd D.J.; Free R.C.; Wain L.V.; Tobin M.D.; Lewis C.M.. - In: MOLECULAR PSYCHIATRY. - ISSN 1359-4184. - STAMPA. - 26:7(2021), pp. 3363-3373. [10.1038/s41380-021-01062-9]
Fabbri C.; Hagenaars S.P.; John C.; Williams A.T.; Shrine N.; Moles L.; Hanscombe K.B.; Serretti A.; Shepherd D.J.; Free R.C.; Wain L.V.; Tobin M.D.; Lewis C.M.
File in questo prodotto:
File Dimensione Formato  
s41380-021-01062-9.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione 1.44 MB
Formato Adobe PDF
1.44 MB Adobe PDF Visualizza/Apri
41380_2021_1062_MOESM1_ESM.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per accesso libero gratuito
Dimensione 6.45 MB
Formato Adobe PDF
6.45 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/850145
Citazioni
  • ???jsp.display-item.citation.pmc??? 30
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 40
social impact